Cover Image

Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial

Background: Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC. Methods: In this openlabel, phase I/II c...

Full description

Saved in:
Bibliographic Details
Main Authors: Ströhlein, Michael (Author) , Lordick, Florian (Author) , Rüttinger, Dominik (Author) , Grützner, Klaus-Uwe (Author) , Schemanski, Oliver C. (Author) , Jäger, Michael (Author) , Lindhofer, Horst (Author) , Hennig, Michael (Author) , Jauch, Karl-Walter (Author) , Peschel, Christian (Author) , Heiss, Markus M. (Author)
Format: Article (Journal)
Language:English
Published: February 18, 2011
In: Onkologie
Year: 2011, Volume: 34, Issue: 3, Pages: 101-108
ISSN:1423-0240
DOI:10.1159/000324667
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000324667
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/324667
Get full text
Author Notes:Michael A. Ströhlein, Florian Lordick, Dominik Rüttinger, Klaus-Uwe Grützner, Oliver C. Schemanski, Michael Jäger, Horst Lindhofer, Michael Hennig, Karl-Walter Jauch, Christian Peschel, Markus M. Heiss
Description
Summary:Background: Peritoneal carcinomatosis (PC) is common in gastrointestinal (GI) cancer and there is no effective standard treatment. We investigated the tolerability and maximum tolerated dose (MTD) of the trifunctional antibody catumaxomab in patients with PC. Methods: In this openlabel, phase I/II clinical trial, patients with epithelial cell adhesion molecule (EpCAM)-positive PC from GI cancer received 4 sequential intraperitoneal catumaxomab infusions: day 0: 10 µg; day 3: 10 or 20 µg; day 7: 30, 50, or 100 µg; and day 10: 50, 100, or 200 µg. Dose escalation was guided by dose-limiting toxicities. Results: The MTD was 10, 20, 50, and 200 µg on days 0, 3, 7, and 10, respectively. Catumaxomab had an acceptable safety profile: Most common treatment-related adverse events (at the MTD) were fever, vomiting, and abdominal pain. At final examination, 11/17 evaluable patients (65%) were progression free: 1 patient had a complete and 3 a partial response. Median overall survival from the time of diagnosis of PC was 502 days. Conclusions: Intraperitoneal catumaxomab is a promising option for the treatment of PC from GI cancer.
Item Description:Gesehen am 25.10.2022
Physical Description:Online Resource
ISSN:1423-0240
DOI:10.1159/000324667

Similar Items